<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345278</url>
  </required_header>
  <id_info>
    <org_study_id>SM/0044</org_study_id>
    <nct_id>NCT02345278</nct_id>
  </id_info>
  <brief_title>SUBLIVAC FIX Mite Mixture Dose Tolerability Study</brief_title>
  <acronym>DTS</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Determine Tolerability and Safety of Different Dosages of SUBLIVAC FIX Mite Mixture in Patients With Allergic Rhinitis / Rhinoconjunctivitis Caused by House Dust Mites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HAL Allergy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HAL Allergy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergic rhinitis/rhinoconjunctivitis is a symptomatic disorder of the nose induced by an&#xD;
      immunoglobulin E (IgE) mediated inflammatory response. Treatment may involve pharmacotherapy&#xD;
      and specific immunotherapy (IT). IT represents the only treatment that might alter the&#xD;
      natural course of the disease. The amount of administered allergen is crucial for both&#xD;
      efficacy and safety of specific IT. SUBLIVAC FIX Mite mixture is a preparation for sublingual&#xD;
      IT (SLIT) and is indicated for the treatment of allergic disorders such as allergic rhinitis&#xD;
      and rhinoconjunctivitis, caused by sensitisation to house dust mite (HDM) allergens.&#xD;
&#xD;
      According to the European Medicines Agency Guideline on the clinical development of products&#xD;
      for specific IT for the treatment of allergic diseases, products should be tested at&#xD;
      different dosages to provide preliminary data on safety and tolerability with regard to the&#xD;
      maximum tolerated dose and suitable dose escalation scheme. This trial is designed to&#xD;
      investigate the tolerability and safety of different dosages of SUBLIVAC FIX Mite mixture.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of SUBLIVAC FIX Mite mixture (assessed by number and severity of local and systemic reactions)</measure>
    <time_frame>1 month treatment</time_frame>
    <description>Safety and tolerability of different dosages of SUBLIVAC FIX Mite mixture compared to placebo assessed by number and severity of local and systemic reactions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 month treatment</time_frame>
    <description>Safety of different dosages of SUBLIVAC FIX Mite mixture compared to placebo assessed by number and severity of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and laboratory parameters (Safety of different dosages of SUBLIVAC FIX Mite mixture)</measure>
    <time_frame>1 month treatment</time_frame>
    <description>Safety of different dosages of SUBLIVAC FIX Mite mixture compared to placebo assessed by clinical and laboratory parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in immunoglobulin levels ((IgE, IgG, IgG4)</measure>
    <time_frame>1 month</time_frame>
    <description>Changes in serum specific immunoglobulin levels (IgE, IgG, IgG4) after 1 month of treatment with different dosages of SUBLIVAC FIX Mite mixture compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients reaching maintenance dose within 10 days</measure>
    <time_frame>10 days</time_frame>
    <description>Proportions of patients in the different treatment groups reaching maintenance dose within 10 days</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>House Dust Mite Allergy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once daily sublingual administration for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SUBLIVAC FIX Mite mixture 10,000 AU/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>once daily sublingual administration for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SUBLIVAC FIX Mite mixture 25,000 AU/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>once daily sublingual administration for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SUBLIVAC FIX Mite mixture 50,000 AU/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>once daily sublingual administration for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SUBLIVAC FIX Mite mixture 100,000 AU/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>once daily sublingual administration for 1 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUBLIVAC FIX Mite mixture</intervention_name>
    <description>Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.</description>
    <arm_group_label>SUBLIVAC FIX Mite mixture 10,000 AU/mL</arm_group_label>
    <arm_group_label>SUBLIVAC FIX Mite mixture 100,000 AU/mL</arm_group_label>
    <arm_group_label>SUBLIVAC FIX Mite mixture 25,000 AU/mL</arm_group_label>
    <arm_group_label>SUBLIVAC FIX Mite mixture 50,000 AU/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Male or female patients, age ≥ 18 ≤ 60 years&#xD;
&#xD;
          3. Patients with allergic rhinitis or rhinoconjunctivitis induced by HDM for at least 1&#xD;
             year, with or without concomitant at least partly controlled asthma&#xD;
&#xD;
          4. Patients with a history of concomitant asthma should have a FEV1 &gt; 70% (of predicted&#xD;
             value) at inclusion. Patients without a history of asthma should have a FEV1 &gt; 70% or&#xD;
             a PEF &gt; 80% (of predicted value)&#xD;
&#xD;
          5. Positive SPT to HDM D. pter or D. far (mean wheal diameter ≥ 3 mm compared to negative&#xD;
             control; negative control should be negative; histamine control should be positive&#xD;
             (mean wheal diameter ≥ 3 mm) at screening&#xD;
&#xD;
          6. Allergen specific serum IgE (ssIgE) level in serum for HDM D. pter or D. far (&gt; 0.7&#xD;
             U/ml), assessed at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with concomitant sensitization i.e. positive SPT (mean wheal diameter ≥ 3 mm&#xD;
             compared to negative control; negative control should be negative; histamine control&#xD;
             should be positive (mean wheal diameter ≥ 3 mm) who are expected to have clinically&#xD;
             relevant symptoms during the treatment period&#xD;
&#xD;
          2. Patients sensitized and symptomatic to pets who are regularly exposed to pets&#xD;
&#xD;
          3. Completed allergen-specific immunotherapy (SCIT or SLIT) with HDM within the last 5&#xD;
             years&#xD;
&#xD;
          4. Completed unsuccessful allergen-specific immunotherapy (SCIT or SLIT) within the last&#xD;
             5 years&#xD;
&#xD;
          5. Allergen-specific immunotherapy (SCIT or SLIT) with other allergens than HDM during&#xD;
             the study period&#xD;
&#xD;
          6. Any other vaccination one week before start of treatment and during the up-dosing&#xD;
             phase&#xD;
&#xD;
          7. Any anti-IgE therapy within the last 6 months prior to inclusion and during study&#xD;
&#xD;
          8. Active inflammatory disease in the mouth (e.g periodontitis, oral mucosal lichen&#xD;
             planus)&#xD;
&#xD;
          9. Known hypersensitivity to any of the excipients (i.e. Disodium phosphate dihydrate,&#xD;
             Sodium dihydrogen phosphate dihydrate, Aminocaproic acid, Glycerol, Peppermint oil,&#xD;
             Caramel Colorant) of SLIT solution&#xD;
&#xD;
         10. Severe immune disorders (including auto-immune diseases) and/or diseases requiring&#xD;
             immunosuppressive drugs&#xD;
&#xD;
         11. Active malignancies or any malignant disease in the last 5 years&#xD;
&#xD;
         12. A chronic or acute disease that in the opinion of the investigator might place the&#xD;
             patient at an additional risk, including but not limited to the following:&#xD;
             cardiovascular insufficiency, any severe or unstable lung diseases, endocrine&#xD;
             disorders, clinically significant renal or hepatic diseases, or haematological&#xD;
             disorders&#xD;
&#xD;
         13. Diseases with a contra-indication for the use of adrenaline (e.g. hyperthyroidism,&#xD;
             glaucoma)&#xD;
&#xD;
         14. Use of systemic corticosteroids 4 weeks before start treatment&#xD;
&#xD;
         15. Treatment with systemic or local beta-blockers&#xD;
&#xD;
         16. Clinically significant chronic sinusitis or ocular infection&#xD;
&#xD;
         17. Participation in a clinical study with a new investigational drug within the last 3&#xD;
             months or a biological within the last 6 months prior to the study or during the study&#xD;
&#xD;
         18. Pregnancy, lactation or inadequate contraceptive measures (acceptable forms of birth&#xD;
             control include Intrauterine devices or hormonal contraception (oral contraceptive&#xD;
             pills, implants, transdermal patches, vaginal rings or long-acting injections) or&#xD;
             condom combined with a diaphragm including spermicidal cream). Also acceptable for&#xD;
             women is surgical sterilization (removal of the uterus or ovaries or tubal ligation&#xD;
             (&quot;tied tubes&quot;)), if they are postmenopausal (12 consecutive months without a period)&#xD;
             for at least 2 years, or having no sexual relationship with a man.&#xD;
&#xD;
         19. Alcohol, drug, or medication abuse within the past year and during the study&#xD;
&#xD;
         20. Any lack of co-operation or compliance&#xD;
&#xD;
         21. Severe psychiatric, psychological, or neurological disorders&#xD;
&#xD;
         22. Patients who are employees of the department or study site; 1st grade relatives,&#xD;
             partners of the investigator, or patients who are dependent on the sponsor&#xD;
&#xD;
         23. Any physical or mental condition that precludes administration of allergen-specific&#xD;
             immunotherapy, compliance or participation in a trial&#xD;
&#xD;
         24. Patients who are placed in an institution due to governmental or judicial directive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margitta Worm, Prof.Dr.med.</last_name>
    <role>Study Chair</role>
    <affiliation>Allergie-Centrum-Charité</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin, Allergiezentrum</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr.med.Elke Hippke</name>
      <address>
        <city>Berlin</city>
        <zip>D-13057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO-Heilkunde Praxis</name>
      <address>
        <city>Chemnitz</city>
        <zip>D-09130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO und Allergologie Praxis</name>
      <address>
        <city>Dresden</city>
        <zip>D-01139</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO-Praxis Dr. Uta Thieme</name>
      <address>
        <city>Duisburg</city>
        <zip>D-47051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Dusseldorf, Department Dermatology</name>
      <address>
        <city>Dusseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO Praxis Gottingen</name>
      <address>
        <city>Gottingen</city>
        <zip>D-37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO Praxis am Neckar</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO Gemeinschaftspraxis</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr.med. Ulrich Neumann Praxis</name>
      <address>
        <city>Wolmirstedt</city>
        <zip>D-39326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>January 19, 2015</study_first_submitted>
  <study_first_submitted_qc>January 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Allergic rhinitis/rhinoconjunctivitis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

